Launch of CardioSAVE Consortium :
Prognostic Biomarkers for Myocardial Infarction
The EU-funded (EUROTRANSBIO) CardioSAVE consortium was launched by Firalis SAS in collaboration with the Bad Krozingen Herzzentrum (Bad Kronzingen, Germany), Scienion AG (Berlin, Germany), the Institute of genetic, molecular and cellular biology (IGBMC) (Strasbourg, France) and the Centre de Recherche Public de la Santé (CRP-Santé, Luxembourg). The 1.9 million Euro research program will involve a large clinical study, supported in part by the Region of Alsace, in order to develop an innovative personalized healthcare tool for patients at high risk of developing complications after an acute cardiac event.
While recent advances in the management of acute myocardial infarction (AMI) have provided a dramatic reduction of the fatality rate during the acute phase of the infarction, it has, however, resulted in an increase of the number of patients likely to develop mid to long-term complications. Indeed, heart failure develops in more than 30% of patients in the five years following the infarction. Heart failure is the main cause of hospital admission in the EU and the prognosis remains poor with 30 to 40% of patients dying within one year and 60 to 70% within 5 years. Preventive therapy has shown to be useful in slowing down the progression of the disease, but implies that patients at risk are identified early. Current tools, such as natriuretic peptides, have proven insufficient and the medical need of these patients remains unmet. The CardioSAVE consortium will capitalize on its existing know-how and intellectual property to develop a diagnostic test that will allow the risk stratification of myocardial infarction patients. This stratification will help clinicians to adapt healthcare to the individual patient in order to reduce the incidence of heart failure.
Bringing together public and private partners with strong expertise in cardiovascular medicines and medical devices, the CardioSAVE consortium constitutes a unique opportunity to translate innovative biomarkers into clinical practice. The availability of such a test would allow more effective treatment and a drastic reduction of the burden of heart failure on healthcare systems.
< CardioSAVE CONSORTIUM >
Participant-1 & Project Coordinator: FIRALIS SAS is a privately owned life sciences company, creating novel values via biomarker discovery, development and regulatory qualifications; to establish an internal portfolio of biomarker-based diagnostic methods and to provide customized biomarker solutions. Firalis is active in the field of drug safety, cardiovascular, inflammatory and autoimmune diseases. The company has been awarded with several national and international prizes for its innovative approaches. Firalis is certified ISO 13485 and ISO 9001 for the development and production of ELISA kits and certified ISO 17025 for testing laboratory.
Participant-2: SCIENION AG is a life sciences company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. The company provides its customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomics and proteomics fields from early research to manufacturing. SCIENION AG is engaged in several joint research projects at a national and international level. SCIENION AG is certified according to DIN EN ISO 9001:2008 for the development, manufacture and sales of dispensing systems and microarrays.
Participant-3: The University Heart Center Freiburg-Bad Krozingen is one of the largest in Europe and offers a full range of the most modern invasive and non-invasive treatments. This center conducts a broad range of scientific research. The Department of Cardiology and Angiology II closely cooperates with specialists of other departments of the University Medical Center Freiburg. This department specializes in the diagnostics and therapy of the heart and arterial vessels diseases.
Participant-4: IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire) is one of the leading European centers of biomedical research and comprises 5 technological platforms and 12 common facilities. The IGBMC is devoted to the study of higher eukaryotic genomes and to the control of genetic expression as well as the analysis of the function of genes and proteins. This knowledge is applied to studies of human pathologies.
Project Collaborator: CRP (Centre de Recherche Public de la Santé), Luxembourg CRP “Cardiovascular Research Group” is a CardioSAVE collaborator with an expertise in prognostic aspects of the development of heart failure following myocardial infarction; owning two patents on biomarkers of heart failure that will be investigated by the CardioSAVE project.